European Commission approves treatment for Duchenne muscular dystrophy

Duvyzat conditionally approved by EC to treat Duchenne MD

The European Comission has conditionally approved Duvyzat (givinostat) to be taken alongside corticosteroids for treating people who are 6 and older with Duchenne muscular dystrophy (DMD). “This milestone means that a broad range of patients with DMD have access to a new treatment,” Francesco De Santis, president of Italfarmaco Holding and chairman of Italfarmaco Group, said in a company press release. “At Italfarmaco, this achievement reaffirms…

European Commission approves treatment for Duchenne muscular dystrophy

Italfarmaco has announced that the European Commission (EC) has granted conditional marketing authorisation for Duvyzat (givinostat), a novel histone deacetylase (HDAC) inhibitor.